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Summary.-The purpose of this study was to use an immunization protocol with
Moloney sarcoma virus (MSV-M) as active immunogen against exogenous and endo-
genous leukaemia. The s.c. route was chosen since it offered advantages over the i.m.
route: the primary sarcomas were smaller, the regression faster, there were fewer
recurrences and there was good persistent immunity. Strong protection was obtained
against primary leukaemias induced by Friend leukaemia virus (FLV), Moloney
leukaemia virus (MLV), Rauscher leukaemia virus (RLV), Precerutti-Law leukaemia
virus (PLLV/T2), and H179A leukaemia virus. It was not possible to protect against
leukaemia induced by Gross leukaemia virus (GLV). With transplantable leukaemias
the results varied: partial protection was observed against H110 leukaemia (induced
with human material) and R14 leukaemia (induced by X-irradiation) whilst no pro-
tection was obtained against P277 leukaemia (induced by Moloney leukaemia virus).
As for spontaneous leukaemias, immunized BALB/c mice showed an increased
incidence over the controls, while in Fl (Swiss x AKR) mice the incidence was similar
but the latent period was shorter. Furthermore, in long-term observations the MSV-
M-immunized mice showed an increased mortality, which could be related to (1)
new phenotypic mixtures between MSV-M and leukaemia viruses; (2) reactivation
of MSV-M sarcoma-genesis with age, and (3) genotype susceptibility to MSV-M.
To DATE, no standardized system has
been used to compare the results of one
and the same immunization protocol on
the prevention of transplanted, primary
and spontaneous leukaemia in the mouse.
However, on different occasions, active
immunization methods have been used,
such as: (1) syngeneic transplantable
leukaemia in sub-threshold doses (Axelrad,
1963; Klein & Klein, 1964; Pasternak &
Graffi, 1963); (2) allogeneic transplantable
leukaemia (Klein & Klein, 1964; McCoy
et al., 1967; Pasternak & Graffi, 1963);
(3) culture cells chronically infected with
virus (Barski & Youn, 1965; Mayyasi et
al., 1968); (4) infectious leukaemia virus
(Bianco et al., 1966; Glynn et al., 1964,
1968; Klein & Klein, 1964; Mayyasi &
Moloney, 1967; McCoy et al., 1967; Sachs,
1962; Slettenmark & Klein, 1962); (5)
attenuated leukaemia virus (Fink &
Rauscher, 1964; Friend, 1959; Huebner
et al., 1976; Kelloff et al., 1976; Mayyasi &
Moloney, 1967; McCoy et al., 1967;
Tyndall, et al., 1967); (6) infectious murine
sarcoma virus (Fefer et al., 1967; Huebner
et al., 1976; Basombrio et al., 1977); and
(7) purified viral components (Hunsmann
et al., 1975; Ihle et al., 1976a,b). Thevaria-
bility among experimentalprotocols makes
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a direct comparison ofthe different results
extremely difficult.
The Moloney sarcoma virus system
(MSV-M) has been well characterized
(Harvey & East, 1971). Its tissue tropism
is different from that ofleukaemic viruses,
since it replicates preferentially in
muscle and not in haemopoietic tissue
(Perk & Maloney, 1966) and induces
atypical granulomas (Simons & McCully,
1970). The tumours induced by MSV-M
in normal adult mice regress after attain-
ing considerable size, leaving the animals
free of disease (Fefer, 1968). Immuno-
logically, MSV-M has been studied ex-
tensively; both the humoral and the
cellular immune responses (Lamon et al.,
1974) have been characterized. It has also
been observed that MSV-M shares anti-
gens with the Friend-Moloney-Rauscher
complex (Fefer et al., 1967); its neutraliza-
tion with rat anti-Gross serum (Fefer,
1967) opened up the possibility of using
this virus for vaccination against Gross
leukaemias.
On the basis of the accumulated data,
MSV-M seems to be the best characterized
ofall murine oncorna viral systems. There-
fore, the purpose of this study was to use
a unique standardized protocol with
MSV-M as a live viral vaccine for the pre-
vention of primary, transplanted and
spontaneous leukaemia in the mouse.
MATERIALS AND METHODS
Mice.-Inbred BALB/c and outbred Swiss
mice, raised in our colony, 2 months old and
of either sex, were used for immunization
against primary and transplanted leukaemia.
(Swiss x AKR) Fl hybrids and BALB/c mice
were used in studies involving spontaneous
leukaemia.
Leukaemia viruses. Six strains of murine
leukaemia virus were used. Lyophilized
Friend leukaemia virus (FLV, Lot 245 No. 5)
frozen Rauscher leukaemia virus (RLV,
Lot No. 1) and lyophilized Gross leukaemia
virus (GLV, Lot 2D) were obtained from the
American Type Culture Collection, Rockville,
Md, U.S.A. Moloney leukaemia virus (MLV)
was obtained from culture fluids of 3T3-
murine leukaemia cells, provided by Dr Saal,
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Centre Hayem, Hopital Saint Louis, Paris,
France.
Precerutti-Law leukaemia virus (PLLV/
T2) was introduced to our laboratory by Dr
Precerutti 10 years ago as a BALB leukaemia
of short latency, propagated by acellular
extracts (Precerutti & Law, 1963). H179A
leukaemia virus (H179A LV) was obtained
from acellular extracts of leukaemia that
appeared in a female BALB/c mouse,2months
of age, 17 days after it had been inoculated
with AKR leukaemic material (Pasqualini
et al., 1968).
Transplantable leukaemias.-Different leu-
kaemias have been induced in our laboratory
in the course of 20 years; many are main-
tained by serial cell passage (Pasqualini et al.,
1968) of which the following were studied:
HlIO Leukaemia, obtained from a 3 month
old BALB female, 37 days after being inocu-
lated with human material via the intra-
splenic route; R14 leukaemia, obtained from
a 10-month-old BALB/c female mouse that
had received 3 weekly doses of 150 rad;
P277 leukaemia, obtained from mice inocu-
lated with Moloney leukaemia virus.
Spontaneous leukaemias.-High- and low-
leukaemia strains were needed for the experi-
ments. (AKR x Swiss) Fl hybrids were used
as a high-leukaemia strain, since they
proved to have a 30% incidence ofleukemia at
an average age of 12 months. The BALB/c
strain was selected as a low-leukaemia strain,
having a 15% spontaneous incidence at an
average age of 18 months, in our laboratory.
Preparation and titration of Moloney sar-
coma virus vaccine.-MSV-M used in the ex-
periments originated from lot SVR-P166
kindly forwarded by Dr. K. E. Hellstrom,
University of Washington, Seattle, U.S.A.
A large number of newborn BALB/c mice
were inoculated. Subcutaneous sarcomas
originating from this inoculum were disrupted
in 10 volumes of cold phosphate-buffer saline
plus streptomycin and penicillin (PBS) and
then homogenized in a Virtis blender Model
S23. The homogenate was centrifuged twice
at 5000 and 10,000 revs/min for 15 and 20
min respectively. Supernatants were then
transferred to glass ampoules, sealed and
frozen at - 196°C for storage.
The titre of MSV-M was calculated in vivo
using the Reed-Muench method, estimating
take doses at Day 35. 0-2 ml of 10-fold dilu-
tions of MSV-M stock were inoculated i.m.
into 2-month-old BALB/c and Swiss mice.
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Stock MSV-M, used in all experiments, con-
tained 1P5 x 10J Take-dose 50/ml.
Preparation and titration of murine leu-
kaemia virus.-Leukaemic tissues (spleen and
lymph nodes) were disrupted in 10 volumes of
PBS with a glass homogenizer and processed
in the same manner as for MSV-M sarcomas.
Murine leukaemia viruses used to challenge
MSV-M immunized mice were titrated in
vivo in 2-3-month-old BALB/c mice. Tenfold
dilutions of stored stock viruses were inocu-
lated i.p., each mouse receiving 0-1 ml, and
the proportion of mice dying with leukaemia
within 3 months was recorded. The titre of
the murine leukaemia viruses used was cal-
culated by the Reed-Muench method esti-
mating lethal doses at the day indicated
between brackets in each case. Titres were:
RLV: 3-7x102 LD50 (69)/ml; FLV: 5x102
LD50 (74)/ml; PLLV-T2LV: 51 x 103 LD50
(66)/ml and H179ALV: 5 x 104 LD50 (56)/ml.
MLV and GLV were not titrated in this way,
since they induced splenomegaly and death
after prolonged periods. Massive doses of
these viruses were inoculated in the challenge
experiments.
Preparation and titration of transplantable
leukaemia cells. Transplantable leukaemias
were maintained by in vivo cellular passage
every 7-14 days. Stock material was prepared
by mincing leukaemic tissues in 10 volumes
of PBS, filtering through a cotton gauze and
storing in glass ampoules, sealed and frozen
at - 196TC for storage. For titration, the
number of viable cells was determined in the
unfrozen stock material by Trypan-blue
exclusion. The concentration was adjusted
so as to inoculate 101-105 cells per mouse in
0-2 ml, i.p. Death by 25 days was recorded
and LD50 calculated. The LD50 of the leu-
kaemias used was respectively: H110: 80
cells in 19 days, R14: 100 cells in 25 days, and
P277: 50 cells in 20 days.
The experimental protocol for immuno-
prevention studies.-In order to test the live
MSV-M immunogen, mice were subjected to a
standardized protocol: inoculation of 0-2 ml
MSV-M s.c. which induced localized sarcomas
which quickly regressed, followed by a booster
immunization 30-40 days later. The control
group received 0-2 ml of a supernatant of
normal BALB/c muscle extracts. Challenge
of the MSV-M immunized mice with either
leukaemia virus or cells was accomplished
30 days after the booster immunization, when
mice were 4 months old. The incidence of
primary and transplanted leukaemiainexperi-
mental and control mice was carefully recor-
ded. All sick animals with evident spleno-
megaly were sacrified and autopsied: presence
of enlarged spleen, thymus or lymph nodes
indicated leukaemia.
The data were evaluated by the x2 and
Mann-Whitney U tests.
RESULTS
Characterization of MSV-M stock
Tumour incidence, tumour growth, sur-
vival rate and immunological status were
studied using different dilutions of
MSV-M stock inoculated either i.m. or
s.c. By s.c. route, tumour incidence
(Table I) and growth (Fig. 1) were greatly
reduced, tumour regression was complete
in all animals and the survival rate was
considerably greater (Table I). MSV-M
challenge of the immunized survivors
TABLE I. Comparison of tumour incidence and survival rate of BALB/c mice inoculated
with MSV-M s.c. and i.an.
S.c. route
I_
Incidence at
Day 35
Tumours/
No. mice* (0
11/12 9
10/12 8
9/12 7
2/10 2
0/1 2
/o)
.3
75
0
D,_
1(
1(
I.m. route
Sur-ival at
--
,y 35 D)av 97
0o/) (0%)
DO 91
M() 100
O( 100
O() t100
Of) 100
Inci(Ience at
Day 35
-_-
Tumouirs/
No. mice*
12/12
12/12
12/12
8/12
0/12
(0)
100
100
loo
66
0
Survival at
-
A
D)ay '35 D)ay 97
(0) (00)
90 30
66 16
100 70
100 100
100 100
* Each mouise received 0-2 ml of MSV-INI, (liluitp(1 from a stock -with a titre of 15 x 105 TD50(35)/ml.
Log of
MSV-M
(lillition
- 1
-3
-4
-5
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FiG. 1.- Tumour growth in BALB/c mice
inoculated with MSV-M s.c. andl i.m.
Tumour size calculated as average of
3 diam. (mm). dilution 10-1 - - - -1
dlilution 10-2; - - - dilution 10-3;
...... (lilution 10-4.
TABLE II. Comparison of tumour inci-
dence (at 35 days) after MSV-M challenge
of BALB/c mice previously MSV-M-
immunized s.c. or i.m.
S.c. route I.m. route
Log Ttumour Tumour
(lilution of takes/ takes/
immunizing total total
inocultum challenged* challengedc %
-I 0/11 0 0/2 0
-2 0/12 0 0/1 0
-3 0/12 0 0/7 0
-4 1/12 8 1/9 10
-5 5/12 41 6/12 50
Controls 8/12 66
* Witlh 0-1 ml of a 10-1 diltution of stock MSV-M
i.m.
showed that the s.c. route immunized as
well as the i.m. one, even though 3 months
had elapsed since tumour regression
(Table II). These data indicated clearly
that with our MSV-M stock the s.c. route
ofimmunization was the better ofthe two.
Immunoprevention of primary miurine
leukaemias
Immunization against Moloney leuk-
aemia.-Since the susceptibility to MLV
decreased with age, adult BALB/c mice
developed a moderate splenomegaly which
progressed slowly, with many mice sur-
viving beyond 1 year, so that immunity
was evaluated by recording the inhibition
of leukaemic splenomegaly (Basombrio et
al., 1977).
A group of 15 MSV-M-immunized
BALB/c mice received 0 5 ml ofMLV i.p.,
x = 207 mg x = 329 mg
800 J
500
450
i 400
.350
@0 ~~~~~00
150 0
u)iso
MSV-M immunized Controls
FIG. 2. Immunization against primary
Moloney leukaemia........Normal spleen.
simultaneously with 15 controls. All mice
were killed on Day 86 and the spleens
weighed. There was a noticeable inhibition
of splenomegaly indicating protection
against Moloney leukaemia (P= 0 02,
Mann-Whitney U test) in the MSV-M
immunizedmice (x=207 mg;s.d.= 44 6mg)
with respect to the controls (x=329 mg;
s.d. = 166 mg).
Immunization against Rauscher leuk-
aemia. Seventeen BALB/c mice immu-
nized with MSV-M, together with 21 con-
trols, received 0-2 ml of a 10-2 dilution of
Survival %
100
90a
80-
70- , *\
60
50
40
30 -
20
10
50 100 150 200 250 300 350
days
FIG. 3. Immunization witlh MSV-M against
primary Rauscher leukaemia. im-
munized with MSV-M; ....... controls.
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TABLE III. Palpable splenomegaly (at 32
days) in BALB/c mice immunized with
MSV-M and challenged with FLV
Group
MSV-M
immunize(l
Controls
Positive
splenomegaly
/Total mice
5/20
16/23
o/
O
25
69
<0-001
* Calculated by x2 test.
the RLV stock. Both groups were ob-
served for 358 days. A clear protection
against the development ofleukaemia was
observed at Day 120 (Fig. 3). 14/17 (82%)
of MSV-M immunized mice surviving
against 4/21 (19%) of the controls
(P < 0'001). Further observation showed
that mortality progressively increased in
both groups, only 4/17 (23%) of the
MSV-M immunized mice and 2/21 (90) of
the controls surviving at 369 days.
Immunization against Friend leukaemia.
A group of 21 MSV-M-immunized
BALB/c mice, together with 23 controls,
were challenged with FLV, each mouse
receiving 0 2 ml of a 1/500 dilution of
FLV stock. The survival rate was similar
in both groups after 169 days of observa-
tion (7/21 immunized and 7/23 controls).
As shown in Table III, there was a sig-
nificant inhibition of palpable spleno-
megaly 32 days after FLV challenge in the
MSV-M immunized group (P < 0-001)
though this difference was not reflected in
the survival data.
Imnmunization against Precerutti-Law
leukaemia.-A group of 19 MSV-M-im-
munized BALB/c mice, together with 18
controls, were challenged i.p. with 0-2 ml
of a 10-3 dilution of PLLV/T2. After 130
days clear protection was seen in the pre-
treated group (Fig. 4) where 13/19 (68%)
survived whereas all the controls had died
(P< 0.001; x2 test). On further observa-
tion, immunized mice showed a pro-
gressive mortality, since after 365 days,
only 6/19 (32%) survived.
Immunization against HI79A leukaemia.
-A group of 14 MSV-M-immunized
BALB/c mice, together with 18 controls,
Survival %
100
90 .
80 \
70
60 K
50 '.\
40
30 N*
20
10
50 100 150 200 250 300 350
days
FIG. 4.-Immunization with MSV-M against
primary PLLV/T2 leukaemia. Key as in
Fig. 3.
were challenged i.p. with 0-2 ml of a 10-3
dilution of H179A LV. At Day 46, 11/14
(78%) of immunized mice survived,
against none of the controls (Fig. 5;
P < 0001, x2 test). The animals were
observed for 137 days, at which time 7/14
(50%o) had survived.
Survival %
100 \_--'
90
80 0
70
60
50
40
30
20
10
20 40 60 80 100 120 140
days
FIG. 5.- Immunization witli MSV-M against
primary H179 A leukaemia. Key as in
Fig. 3.
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Survival % Survival %
100 F-
90
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20
10
100
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50
40
30
20
10
40 80 120 160 200 240 2'89
days
FIG. 6. Immunization with MSV-M against
primary Gross leukaemia. Key as in Fig. 3.
Immunization against Gross leukaemia.
-A group of 20 MSV-M-immunized
Swiss mice, together with 22 controls,
were challenged i.p. with 0-2 ml of a GLV
supernatant. After 296 days, 9/20 (45%)
immunized and 7/22 (31%) of control
mice had survived (Fig. 6). There is no
protection by MSV-M imnmunization
against the development of Gross leuk-
aemia.
Imnmunoprotection oftransplantable murine
leukuaemias
Immunization against HI1O leukaemnia.
-A group of 22 MSV-M-immunized
BALB/c mice and 21 matched controls
received 400 H1110 leukaemic cells in
0-2 ml i.p. Thirteen days after challenge,
21/22 (950) of the immunized mice sur-
vived, compared to only 9/21 (47%o) of
the controls (P < 0001; Fig. 7). However,
this significant inhibition of leukaemia
was eventually lost, since at Day 165 6/22
(27%) of immunized and 4/21 (19%) of
control mice survived. Protection against
H1110 leukaemia was evident, but not
long-lasting.
Immunization against R14 leukaemia.-
A group of 17 MSV-M-immunized BALB/c
mice and 16 controls received 103 R14
10 20 30 40 50 100 165
days
FIG. 7.- Immunization with MSV-M against
transplantable HIIO leukaemia. Key as in
Fig. 3.
leukaemic cells in 0.2 ml i.p. Forty-four
days later 12/17 (70%) of immunized and
6/16 (37%) of control mice survived
(P<0 001; Fig. 8). However, at Day 102
only 1/17 (6%) of immunized and 3/16
(18%) of control mice survived. Thus,
protection against R14 leukaemia was
evident but not long-lasting.
ImmunizationagainstP277 leukaernia.-
A group of 19 MSV-M-immunized mice
Survival %
100 LO
90
-
80
-
70 "'*I
60 *
50
40
-
30-
20
-
10 o
15 30 45 60 75 90 105
days
FIG. 8. Immunization with MSV-M against
transplantable RI4 leukaemia. Key as in
Fig. 3.
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and 20 controls received only 14 cells of
P277 leukaemia in 0-2 ml, i.p., since this
leukaemia was highly lethal in very small
cell doses. Neither the immunized nor the
control mice survived more than 14 days,
all mice dying of progressive leukaemia,
against which it was not possible to detect
any protection.
MSV-M immunization against spontaneous
leukaemias
Effect in BALB/c mice.-A group of 47
BALB/c mice received 3 consecutive
MSV-M inoculations at 3, 4 and 9 months
of age, while 51 matched controls re-
mained untreated. After 504 days of
observation (Fig. 9) mortality was greater
Survival
90 . '0
80 0.
60
50 - 0
40
30
20
10
250 300 350 400 450 500 550
days
FIG. 9. Immunization against spontaneous
leukaemia in BALB/c mice. Key as in Fig. 3.
in the immunized than in the control
mice; 29/36 (55%o) of the observed deaths
in the MSV-M-immnunized group occurred
between 300 and 370 days of age, which
was 30 days after the final MSV-M booster
inoculation. An analysis of leukaemia
incidence (Table IV) showed that 4 con-
firmed and 14 presumptive leukaemias
appeared in the immunized group and
only 1 in the controls. This protocol
actually increased the incidence of spon-
taneous leukaemia in BALB/c mice.
Effect in (Swiss x AKR) F1 mice.
(Swiss x AKR) F1 mice presented a 350o
incidence of spontaneous leukaemia in an
average of 18 months. In this experiment
only one inoculation of MSV-M was used
to immunize the mice, in order to reduce
TABLE IV. Incidence ofspontaneous leuk-
aemias in MSV-M-immunized BALB/c
mice observedfor 504 days
MSV-MI
immtunized Controls
Leukaemia
Palpable spleens + lymph
nodes*
Normal
Other causes ofdleath*
Other tumours
Total
* Mice died suddenly so
possible.
4 1
14
11 27
18 22
1
47 51
that no necropsy was
Sunrival °O
100
90
80
70
60
50
40
30
20
10
150 200 300 350 400 450 500 330
days
FiG. 10. Immunization against spontaneous
leukaemia in F1 (Swiss x AKR) mice. Key
as in Fig. 3.
the possibility of increased mortality as
seen in MSV-M-immunized BALB/c mice.
After 528 days of observation (Fig. 10)
both the MSV-M-immunized and the con-
trol mice showed a very similar pattern of
mortality. However, pathological observa-
tion demonstrated that although the inci-
I
I10
tf 9
9 8
= 7
,, 6
0
5
4
r-: 3
m 2
i1
It-
0 If
7 8 9 10 l1l 12 13 14 15 16 17 18
Mornths (;age)
FIG. 11. Immunization against spontaneous
leukaemia in F1 (Swiss x AKR) mice. Key
as in Fig. 3.
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dence of leukaemia in both MSV-M-
immunized (10/42, 23%) and control
(11/47, 27°,) groups was similar, the
leukaemias appearing in the MSV-M-
immunized mice up to 13 months of age
had shorter latency than those seen in the
controls (P < 0.02) (Fig. 11). Thus this
protocol did not prevent spontaneous
leukaemogenesis in (Swiss x AKR) F1
hybrids, but rather accelerated the onset
ofleukaemia.
DISCUSSION
Because of the different biological be-
haviour of MSV-M strains (Lavrin et al.,
1973) our studies began with an immuno-
logical and virological characterization of
the MSV-M viral strain to be used. The
s.c. route of inoculation was chosen be-
cause it induced smaller tumours which
regressed more rapidly, so that survival
was greater, though the immunity in-
duced was as strong as with the i.m. route.
Moreover, the long-term pathogenicity
responsible for recurrences of sarcoma in
sites different from the first inoculation
(diaphragm, spleen, liver) was also sig-
nificantly reduced. The explanation may
be that in the s.c. region there is less
muscular tissue available for the replica-
tion of the virus with special tropism for
this tissue. The effectiveness ofthe experi-
mental protocol using MSV-M as a live
vaccine for immunoprevention studies
was confirmed in the first group of experi-
ments in which immunized mice were
challenged with FLV, RLV7 and MLV, also
used in other laboratories for immuno-
prevention assays. Extension of the ex-
periments to other leukaemia viruses
originating in our laboratory showed
effective protection against primary leuk-
aemias induced by PLLV and HI79A/LV.
However, although serological data (Fefer,
1967) and in immunization with MSV-G
(Basombrio et al., 1977) have indicated the
presence ofcross-reacting antigens in GLV'
and MSV-M, no significant protection
against GLV could be detected.
Transplantable cellular leukaemias,
negative to sensitive in vivo virus onco-
genicity assays, were also tested. It was
observed that the evolution of H110
leukaemia, and to a lesser degree R14
leukaemia, could be retarded. However,
P277, an extremely fast-growing and
lethal leukaemia, could not be prevented,
in spite of being originally induced by
Moloney virus.
The studies on the effect of MSV-M
immunity on spontaneous leukaemo-
genesis in BALB/c and (Swiss x AKR) F1
hybrids were complicated by difficulties
related to long-term observations. In
BALB/c mice, which had received 3
MSV-M injections, mortality was in-
creased: MSV-M was shown to exist in
leukaemic spleens of these mice, since
acellular s.c. passage led to local growth
of sarcoma. This increased mortality was
not found in the (Swiss x AKR) F1
hybrids, probably because only one MSV-
M immunizing dose was used; leukaemia
incidence was similar in both experimental
and control groups, MSV-M-immunized
mice showing significantly earlier spon-
taneous leukaemia up to 13 months ofage.
Long-term observation of MSV-M-
immunized mice challenged with leuk-
aemia viruses, transplantable leukaemias
or controlled for the incidence of spon-
taneous leukaemias, revealed increased
mortality. How can this be explained? In
the first place, in vivo interaction between
infectious FLV, MLV, RLV and MSV-M
could increase the oncogenicity of MSV-M
(Chirigos et al., 1968; Turner & Chirigos,
1969). New phenotypic mixtures might
assemble between the inoculated leuk-
aemia virus and the MSV-M used for
immunization (Chieco-Bianchi et al., 1975).
In certain mouse strains, notably C58 and
AKR, the MSV-M forms phenotypic mix-
tures with the endogenous GLV, pro-
ducing new pseudotypes that could induce
sarcomas of lethal and progressive growth
(Chieco-Bianchi et al., 1974). Thus pheno-
typic mixing could provide new genetic
information which would modify the
biology and pathogenicity of the original
pseudotype used as immunogen. Secondly,
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it has been observed that after regression
of MSV-M-induced sarcomas the virus
remains in the lymphoid tissues of the
mouse as a persistent infection controlled
by the host (Chieco-Bianchi & Collavo,
1976; Giuliani et al., 1973). On the other
hand, 6-month-old mice show again a
great sensitivity to MSV-M oncogenesis
(Pazmifio & Yuhas, 1973). Thus renewed
MSV-M sarcomagenesis might cause un-
expected mortality in long-term experi-
ments due to reactivation of the virus.
Thirdly, the genotype of mice has a great
bearing on the result of MSV-M onco-
genesis: BALB/c mice are known to be
very susceptible, whilst (Swiss x AKR) F1
hybrids are very resistant (Colombatti et
al., 1975) which could account for the
observed difference in mortality.
Could inactivation of the immunizing
MSV-M virus override these difficulties?
Probably not, since recent observations
have shown that the protein fraction gp7l
from FLV inoculated in C57 and AKR
mice produces viral activation (Ihle et al.,
1976a). This would suggest a mechanism
mediated by viral components, an effect
capable of complicating any study on the
viral immunoprevention of murinie leuk-
aemia. The blocking of viral replication
would not be a sufficient guarantee to
hinder the activation of endogenous virus
whichwouldleadto leukaemic transforma-
tion in mice subjected to long observation.
Recapitulating, our protocol, using a
live MSV-M vaccine, proved successful in
short-term experiments, protecting against
the induction of primary leukaemias and
partially against transplantable leuk-
aemias. It was not possible, however, to
obtain protection against spontaneous
leukaemias.
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